KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (Diluted Average): 2013-2024

Historic Shares Outstanding (Diluted Average) for Travere Therapeutics (TVTX) over the last 12 years, with Dec 2024 value amounting to $78.9 million.

  • Travere Therapeutics' Shares Outstanding (Diluted Average) rose 31.94% to $102.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.6 million, marking a year-over-year increase of 31.94%. This contributed to the annual value of $78.9 million for FY2024, which is 6.22% up from last year.
  • As of FY2024, Travere Therapeutics' Shares Outstanding (Diluted Average) stood at $78.9 million, which was up 6.22% from $74.3 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $78.9 million in FY2024 and a low of $47.5 million during FY2020.
  • In the last 3 years, Travere Therapeutics' Shares Outstanding (Diluted Average) had a median value of $74.3 million in 2023 and averaged $72.3 million.
  • Data for Travere Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY grew of 25.86% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Travere Therapeutics' Shares Outstanding (Diluted Average) stood at $47.5 million in 2020, then grew by 25.86% to $59.8 million in 2021, then climbed by 6.56% to $63.8 million in 2022, then grew by 16.48% to $74.3 million in 2023, then grew by 6.22% to $78.9 million in 2024.